Loading…
Loading…
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia PR Newswire
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing
BATON ROUGE, La., Aug. 12, 2026 /PRNewswire/ -- Bernhard Capital Partners ("Bernhard"), an infrastructure and services-focused private markets investment firm, announced today that it has closed on its previously announced acquisition of New Mexico Gas Company ("NMGC") from Emera Inc. ("Emera") (TSX/NYSE: EMA).
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) today announced the transaction to sell New Mexico Gas Company (NMGC), a regulated natural gas utility headquartered in Albuquerque, New Mexico, to Bernhard Capital Partners has closed. The sale of NMGC was originally announced on August 5, 2024. About Emera Inc. Emera (TSX/NYSE: EMA) is a leading North American provider of energy services headquartered in Halifax, Nova Scotia, with investments in regulated electric and natural g.
Emera TSE: EMA reported second-quarter adjusted earnings of C$212 million, or C$0.69 per share, as the utility advanced asset sales designed to strengthen its balance sheet and concentrate investment on its regulated businesses.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (“Emera”) (TSX/NYSE: EMA) reported 2026 second quarter financial results1. Highlights Delivered Q2 2026 adjusted EPS2 of $0.69 and reported EPS of $0.34. Positioned to achieve 2026 adjusted EPS2 growth above the annual target range of 5-7%3 and remain committed to 5-7% adjusted EPS2 growth through 20303. Strengthened year-to-date operating cash flow4 by 8% versus the first six months of 2025. Safely advanced more than $1.7B of customer-focused i.
[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of tran
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the